SCHEMBL4067658

SCHEMBL4067658

c1ccc(CCNc2ncnc3cc(-c4ccccc4)sc23)cc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 9/20 0.61
EGFR P00533 7/20 0.57
MAPK1 P28482 2/20 0.57
LMNA P02545 2/20 0.57
APP P05067 1/20 0.57
HTT P42858 1/20 0.57
IKBKB O14920 1/20 0.55
KDR P35968 2/20 0.50
CCNC P24863 1/20 0.50
CDKN1A P38936 1/20 0.50
CDK8 P49336 1/20 0.50
CDK19 Q9BWU1 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
TYK2 P29597 1/20 0.50
PRKCI P41743 1/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
RCE1 Q9Y256 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4069349 0.94 FLT1 (0.57) FLT1EGFRMAPK1LMNAAPP
SCHEMBL4071814 0.92 FLT1 (0.55) FLT1EGFRMAPK1LMNAAPP
SCHEMBL4072529 0.92 TYK2 (0.60) FLT1EGFRMAPK1LMNAAPP
SCHEMBL4069671 0.90 NPR1 (0.54) FLT1EGFRMAPK1LMNAAPP
SCHEMBL4066934 0.87 CA1 (0.54) FLT1EGFRLMNAHTTIKBKB
SCHEMBL3930448 0.85 FLT1 (0.56) FLT1EGFRMAPK1LMNAHTT
SCHEMBL4072402 0.84 HTT (0.48) FLT1EGFRMAPK1LMNAAPP
SCHEMBL13242725 0.84 AURKA (0.59) FLT1EGFR
SCHEMBL3936767 0.82 NPR1 (0.61) FLT1EGFRMAPK1LMNAIKBKB
SCHEMBL4068423 0.82 MAP3K8 (0.51) FLT1EGFRHTTKDRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP claimed
US-20220402935-A1 HETEROCYCLIC COMPOUND FIMECS, INC. (JP) 2022-12-22 US disclosed
EP-4006037-A1 HETEROCYCLIC COMPOUND Fimecs, Inc. (JP) 2022-06-01 EP disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP disclosed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 FLT1 3521/4885EGFR 875/4885MAPK1 1719/4885
US-20220402935-A1 HETEROCYCLIC COMPOUND IRAK1, IRAK2, IRAK4 FLT1 1577/4885EGFR 814/4885MAPK1 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.